FDA Panel Recommends Loosening Regulations on Peptide Treatments

The market for peptides is set for significant changes following recent developments. Peptides, which are chemicals increasingly marketed as medical treatments and wellness products, have gained attention this week. A panel from the Food and Drug Administration (FDA) cast votes on Thursday and Friday, resulting in a recommendation to ease regulations on six specific peptide treatments.

This decision, however, will not take immediate effect. The FDA will make a final ruling based on the panel’s recommendation, a process that might take several months.